Auvelity and Rexulti are both FDA-approved to treat agitation in people with Alzheimer's disease, but they belong to different drug classes and work in different ways. Auvelity is a non-antipsychotic pill combining dextromethorphan and bupropion, while Rexulti (brexpiprazole) is an atypical antipsychotic that carries a boxed warning about increased risk of death in elderly dementia patients.
Agitation—restlessness, pacing, verbal outbursts, or aggression—affects a large share of people with Alzheimer's and drives much of the strain on caregivers. Choosing between these two drugs comes down to how they work, their safety records, and how strong the evidence is behind each. This page compares them so you can discuss the options with a prescriber.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- The core difference: drug class and safety warning
- How each drug works in the brain
- What the trial evidence shows
- Timelines, approvals, and other uses
- How to weigh the choice with a prescriber
- Frequently Asked Questions
The core difference: drug class and safety warning
The single biggest distinction is drug class. Rexulti is an atypical antipsychotic, the same broad family as drugs used for schizophrenia. Auvelity is not an antipsychotic at all. That difference matters most on the label's warnings.
Like all antipsychotics, Rexulti carries a boxed warning—the FDA's strongest—for increased mortality in elderly patients with dementia-related psychosis, as Otsuka and Lundbeck noted at approval. Auvelity's label does not carry that class warning, and its trials showed discontinuation rates from side effects matching placebo, according to BrightFocus's summary of the approval. When the FDA approved Auvelity, it described the drug as the first non-antipsychotic approved for dementia agitation, per the FDA press announcement. For families wary of antipsychotic risks, that framing is the headline.
How each drug works in the brain
The two drugs act on entirely different brain systems. Rexulti modulates dopamine and serotonin, the standard targets for antipsychotic medications. Auvelity works through a separate pathway.
Its active ingredient dextromethorphan blocks NMDA receptors and stimulates sigma-1 receptors, while the bupropion component inhibits an enzyme (CYP2D6) that would otherwise break dextromethorphan down—keeping blood levels high enough to work. Psychiatric Times explains this mechanism in its coverage of the approval. Neither mechanism is a cure for the underlying disease. Both aim to reduce agitation symptoms, not slow Alzheimer's itself.
What the trial evidence shows
Rexulti's approval rested on Phase 3 trials that showed reduced agitation compared with placebo, measured on the CMAI (a standard agitation rating scale). The Alzheimer's Association noted that roughly 45% of people with Alzheimer's experience agitation, underscoring the need. Auvelity's evidence is more mixed.
Its ADVANCE-1 trial met its CMAI goal, but the larger ADVANCE-2 trial in 408 patients missed its primary endpoint (a −13.8 change versus −12.6 for placebo), as documented by ALZFORUM. A separate long-term study, ACCORD, met its goal of preventing relapse. The practical takeaway: Rexulti has a more consistent efficacy signal across its pivotal trials, while Auvelity's benefit was clear in some studies but not others. A prescriber weighs that against Auvelity's cleaner safety profile.
Timelines, approvals, and other uses
Rexulti came first for this use. It was approved on May 10, 2023 as the first treatment for Alzheimer's-associated agitation. Auvelity followed on April 30, 2026, as Axsome Therapeutics announced. Both drugs were already approved for other conditions before treating agitation.
Auvelity was approved for major depression in August 2022, and Rexulti was first approved in 2015 for schizophrenia and as an add-on for depression, per Drugs.com's approval history. That background matters for two reasons. A person may already be taking one of these drugs for depression, which could shape the choice. And a longer track record—Rexulti has been on the market since 2015—means more accumulated real-world safety data.
How to weigh the choice with a prescriber
No single factor decides this. Bring these points to the appointment: Only a clinician who knows the full medical history can make the call. These drugs treat symptoms, so the plan should include a way to measure whether agitation actually improves.
- **Safety priority:** If avoiding antipsychotic mortality risk is the top concern, Auvelity's lack of a boxed warning favors it.
- **Efficacy track record:** If a consistent, proven effect matters most, Rexulti's trials were more uniformly positive.
- **Current medications:** Note any existing use of bupropion, dextromethorphan, or antipsychotics to avoid duplication or interactions.
- **Other conditions:** Co-existing depression may make one drug do double duty.
- **Response and monitoring:** Either drug should be reviewed regularly to confirm it is helping and to watch for side effects.
Frequently Asked Questions
Is Auvelity safer than Rexulti for dementia patients?
Auvelity's label lacks the antipsychotic boxed warning for increased mortality that Rexulti carries, and its side-effect discontinuation rate matched placebo. But safety depends on the individual, so a prescriber must judge each case.
Can these drugs be taken together?
There is no established combined use for agitation, and both act on overlapping systems. A prescriber would typically choose one, not both.
Do either of these drugs slow Alzheimer's disease?
No. Both target agitation symptoms only; neither is a treatment for the underlying disease.
